Literature DB >> 2693918

Nandrolone decanoate treatment of post-menopausal osteoporosis for 2 years and effects of withdrawal.

C Hassager1, B J Riis, J Pødenphant, C Christiansen.   

Abstract

This study investigated the effects of nandrolone decanoate (ND) therapy (50 mg i.m. every 3 or 4 wk) on bone mass and soft tissue body composition in post-menopausal women. Twenty-two (22) women were followed up over a period of 30 mth, during which they received ND therapy for 12-24 mth and were treatment-free for the other 6-18 mth. While they were receiving treatment forearm bone mineral content (BMC) and lean body mass (LBM) increased, whereas fat mass (FM) decreased. After withdrawal of ND therapy the BMC, LBM and FM values all tended to return to pretreatment levels. Serum high-density-lipoprotein cholesterol showed a non-significant decrease, while serum low-density-lipoprotein cholesterol and serum total cholesterol remained unchanged during therapy. It was concluded that ND therapy can achieve an increase in BMC in post-menopausal women, but this is maintained only for as long as therapy is continued.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2693918     DOI: 10.1016/0378-5122(89)90027-3

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  5 in total

1.  Indicators of bone formation in weight lifters.

Authors:  M K Karlsson; P Vergnaud; P D Delmas; K J Obrant
Journal:  Calcif Tissue Int       Date:  1995-03       Impact factor: 4.333

Review 2.  Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis.

Authors:  P Geusens
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

3.  Mechanical properties, bone mineral content, and bone composition (collagen, osteocalcin, IGF-I) of the rat femur: influence of ovariectomy and nandrolone decanoate (anabolic steroid) treatment.

Authors:  J Aerssens; R Van Audekercke; P Geusens; L P Schot; A A Osman; J Dequeker
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

4.  The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy.

Authors:  C Hassager; L T Jensen; J Pødenphant; K Thomsen; C Christiansen
Journal:  Calcif Tissue Int       Date:  1994-01       Impact factor: 4.333

5.  Nandrolone decanoate administration does not attenuate muscle atrophy during a short period of disuse.

Authors:  Astrid M H Horstman; Evelien M P Backx; Joey S J Smeets; Gabriel N Marzuca-Nassr; Janneau van Kranenburg; Douwe de Boer; John Dolmans; Tim Snijders; Lex B Verdijk; Lisette C P G M de Groot; Luc J C van Loon
Journal:  PLoS One       Date:  2019-01-28       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.